In our next study, we will increase the sample size to reevaluate whether plasma t-tau levels predict cognitive function and AD pathology and assess the utility of plasma p-tau levels for discriminating patients with AD from controls in the Chinese population. The gene discussed is MAPT; the disease is Alzheimer disease.